Concomitant medications
attention-deficit/hyperactivity disorder
BLIND
Concomitant use of antidepressants other than the investigational drug was prohibited during the screening, the open-label period, and the double blind period. Only ramelteon or suvorexant was permitted as concomitant hypnotic agent, and the concomitant use of both drugs was prohibited. Patients who received hypnotic agents in the open-label period were allowed to receive the same agent in the double-blind period only at specific doses and dosages.Other important prohibited concomitant medications included MAO inhibitors, anxiolytics, antipsychotics, antiepileptics, antiparkinsonism, antidementia, attention-deficit/hyperactivity disorder medications, lithium carbonate, and pimozide.